• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Torii Shares Positive Data From Japan Trial of TO-208 for Molluscum Contagiosum


The confirmatory phase 3 trial demonstrated significant efficacy of TO-208 versus a placebo.

Lukassek/Adobe Stock
Lukassek/Adobe Stock

Verrica Pharmaceuticals Inc. and its partner, Torii Pharmaceutical Co., Ltd., today shared positive top-line results from the phase 3 trial of TO-208, also known as VP-102, and marketed as YCANTH in the US, for the treatment of molluscum contagiosum in Japan.

The confirmatory phase 3 trial, conducted in Japan, utilized a double-blind, randomized, parallel-group comparison design to assess the efficacy and safety of TO-208 versus a placebo.

Administered once every 21 days for up to 4 applications, the study aimed to evaluate the clearance of treatable molluscum lesions.

The results demonstrated a statistically significant proportion of subjects achieving complete clearance, the primary efficacy endpoint, compared to the placebo. Safety signals were consistent with previous research, with TO-208 being well-tolerated among participants.

The positive results pave the way for Torii to submit a manufacturing and marketing application for TO-208 in Japan, following the signing of an exclusive licensing agreement signed in March 2021 between Verrica and Torri.

Ted White, the Chief Executive Officer of Verrica Pharmaceuticals, expressed enthusiasm about the promising outcome.

“We are obviously excited by the positive results from this confirmatory Phase 3 trial for TO-208 for the treatment of molluscum in Japan, which underscores the consistent safety and efficacy of VP-102 and FDA-approved YCANTH,” White said in a press release. “We believe Torii is an ideal partner to bring the product to people with molluscum in Japan, and these positive results take us one step closer towards achieving our goal of addressing this large and underserved patient population.”


Verrica Pharmaceuticals’ development and commercialization partner, Torii Pharmaceutical Co., Ltd., announces positive top-line results from a confirmatory phase 3 trial of to-208 for the treatment of molluscum contagiosum in Japan. Yahoo! Finance. December 15, 2023. Accessed December 15, 2023. https://finance.yahoo.com/news/verrica-pharmaceuticals-development-commercialization-partner-110000548.html

Related Videos
© 2024 MJH Life Sciences

All rights reserved.